Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

Percheron Therapeutics says it will abandon its lead drug candidate altogether, following December's Duchenne muscular dystrophy trial flop.

Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and ... dystrophy type 1 (DM1) and ...

Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD: Basel Tuesday, January 28, 2025, 11:00 Hrs [IST] Roche announced posit ...

Courtney Banks, 31, tells PEOPLE about being awake during her BBL procedure, which she likens to "going to the dentist" ...

CONNECT1 has enrolled two cohorts of boys and young men living with DMD amenable to exon 51 skipping ... exon skipping, and muscle tissue concentration. The 10 mg/kg cohort is fully enrolled ...

The GoFundMe page was set up to raise money to cover the cost of life-saving treatment for the 14-year-old boys, who suffer ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

While some forms of MD, like Duchenne Muscular Dystrophy, primarily affect boys ... Over time, healthy muscle tissue is replaced by fat and fibrous tissue, making mobility increasingly difficult.